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TrBackground.Outcome after liver transplantation (LT) is determined by donor, transplant and recipient risk factors. These factors
may have different impact on either patient or graft survival (outcome type). In the literature, there is wide variation in the use of out-
come types and points in time (short term or long term). Objective of this study is to analyze the predictive capacity of risk factors
and risk models in LTand how they vary over time and per outcome type.Methods. All LTs performed in the Netherlands from
January 1, 2002, to December 31, 2011, were analyzed with multivariate analyses at 3-month, 1-year, and 5-year for patient and
(non-)death-censored graft survival. The predictive capacity of the investigated risk models was compared with concordance
indices. Results. Recipient age, model for end-stage liver disease sodium, ventilatory support, diabetes mellitus, hepatocel-
lular carcinoma, previous malignancy, hepatitis C virus antibody, hepatitis B virus antibody, perfusion fluid, and Eurotransplant
donor risk index (ET-DRI) had significant impact on outcome (graft or patient survival) at 1 or multiple points in time. Significant
factors at 3-month patient survival (recipient age, model for end-stage liver disease sodium, ventilatory support) were used to
compose a concept model. This model, had a higher c-index than the balance-of-risk score, DRI, ET-DRI, donor-recipient
model and simplified recipient risk index for long-term patient and non–death-censored graft survival. Conclusions. In this
study, the effects of recipient risk factors and models on different outcome types and time points were shown. Short-term pa-
tient survival mainly depends on recipient risk factors, long-term graft survival on donor risk factors and is more difficult to pre-
dict. Next to the concept model, the donor-recipient model has a higher predictive capacity to other risk models for (long-term)
patient and non–death-censored graft survival. The DRI and ET-DRI best predicted death-censored graft survival. Knowledge
about risk factors and models is critical when using these for waitlist management and/or help in organ allocation and
decision-making.
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2 Transplantation DIRECT ■ 2018 www.transplantationdirect.comOutcome after liver transplantation (LT) is determinedby multiple factors, among which donor, transplant
and recipient risk factors play a crucial role. Previous studies
have identified several of these risk factors and computed risk
models in an attempt to predict this outcome. The survival
outcomes following liver transplantation (SOFT) score,1
donor model for end-stage liver disease (D-MELD),2 the
balance of risk (BAR) score3 and risk model by Burroughs
et al4 all use combinations of donor, transplant and recipient
factors in 1 model, whereas the donor risk index (DRI)5 and
Eurotransplant DRI (ET-DRI)6 consist of donor and trans-
plant factors.
Donor and transplant risk is best indicated by the DRI5 for
the United Network for Organ Sharing (UNOS) region and
ET-DRI6 for the Eurotransplant region. Our recent study
on donor-recipient matching demonstrated that the use of a
combination of a donor risk model with a recipient risk
model in a donor-recipientmodel (DRM) had a better predic-
tion of outcome after LT, than a donor model or recipient
model alone.7 One of the drawbacks of this study was the
fact that the recipient model only consisted of an analysis
with basic recipient-related factors that are registered in the
Eurotransplant database. These basic recipient factors were
used to create a “simplified” recipient risk index (sRRI). An
analysis to create a recipient risk model that encompasses
more factors might be more accurate for the prediction of pa-
tient or graft survival after LT.
When evaluating donor risk models and donor-recipient
risk models computed with data from large registries (Organ
Procurement and Transplantation Network, European Liver
Transplant Registry, Eurotransplant and the UK) in the past
decade (Table 1), it is remarkable that every model is either
based on patient survival or graft survival, with either short
or long-term follow-up. Ideally, relevant information on
pretransplant risk factors that influence posttransplant out-
come should be available at the time of an organ offer. How-
ever, when choosing one of the above described models, one
should at that time already have the desired endpoint in
mind. A sophisticated tool to assess the specific risks of the re-
cipient at multiple time points, that looks at patient as well as
graft survival, does not yet exist. Furthermore, when analyz-
ing and reporting results and comparing them with the liter-
ature, these results should always be interpreted in the light of
donor quality and recipient risks involved.TABLE 1.
Donor and/or recipient risk models in the past decade with diffe
(short-/long-term survival)
Authors Year Model N
Adam et al 2000 Normalized intrinsic mortality risk 22089
Burroughs et al 2006 3- and 12-mo mortality 34664
Feng et al 2006 DRI 20023
Rana et al 2008 SOFT 21673
Halldorson et al 2009 D-MELD 17942
Dutkowski et al 2011 BAR 37255
Braat et al 2012 ET-DRI 5723
Blok et al 2015 sRRI 4466
Collett et al 2016 DLI 7929
D, donor; T, transplant; R, recipient; DLI, donor liver index; ELTR, European Liver Transplant Registry.The objective of this study is to analyze the varying risk
and predictive capacity of (recipient) risk factors and risk
models in LT in the Netherlands. To achieve this, we have to
determine how the risks of these factors vary over time (impact
at short versus long term survival) and per different types of
outcome (patient versus graft survival). Furthermore, we
compare these risk factors with existing risk models.MATERIALS AND METHODS
Study Design
Data from all LTs (including repeated transplants)
performed in the Netherlands from January 1, 2002, to
December 31, 2011, were included. Patients transplanted
with a combined transplant were excluded, except for pa-
tients transplantedwith a combined liver-kidney transplanta-
tion. All livers were recovered from deceased donors and
were transplanted into adult recipients (≥18 years). Donor,
transplant, basic recipient factors, and follow-up data were
obtained from the Netherlands Organ Transplant Registry,
with consent of the scientific advisory committee and the de-
partment heads of the 3 Dutch liver transplant centers. De-
tailed information on recipient characteristics and follow-up
were obtained directly from the transplant centers. No ethical
statement was required according to European guidelines and
Dutch law because data were anonymized, and patients were
not (directly) involved and/or affected.
Statistical Analysis
All available recipient characteristics (Table 2) were in-
cluded in the statistical analysis. The ET-DRI was calculated
to include donor risk in the multivariate analyses.6 In case of
missing values for donor gamma-glutamyltransferase (GGT)
and/or cold ischemia time (CIT) median values were used
(GGT 28 U/L in 1.8% missing of the total, CIT 7.67 h in
0.9%missing of the total) to calculate the ET-DRI. For all re-
cipients, the most recent model for end-stage liver disease
(MELD) score before transplantation was calculated using
the original formula with a lower limit of 1 for all variables
and with creatinine capped at 4 mg/dL.8 If patients received
renal replacement therapy according to Eurotransplant, the
creatinine value was set at 4 mg/dL (as of December 16,
2006, implementation of theMELD score for liver allocation
in the Eurotransplant region).9 TheMELD score was cappedrent end points (patient/graft survival) at different time points
Endpoint
Factors Registry Patient survival Graft survival
D, T, R ELTR 1, 3, and 5 y —
D, T, R ELTR 3, 12 mo —
D, T OPTN — 3 y
D, T, R OPTN 3 mo —
D, R OPTN 1, 4 y 1, 4 y
D, T, R UNOS 3 mo —
D, T Eurotransplant — 2.5 y
R Eurotransplant — 3.3 y
D, T UK — 1, 2, 5, and 10 y
TABLE 2.
Characteristics of all recipients transplanted in theNetherlands
from 2002 to 2011
Recipient factors
Age, median (IQR), y 52 (43-59)
Age category, n (%)
8-39 201 (20)
40-49 232 (23)
50-59 352 (35)
60-69 225 (22)
≥ 70 2 (0.2)
Sex, n (%)
Male 629 (62)
Female 383 (38)
BMI, median (IQR) 24.8 (22.4-27.8)
Etiology (primary reason for LT)
Acute liver failure, primary 92 (9.1)
Cirrhosis, alcoholic 156 (15)
Cirrhosis, hepatitis C-related 115 (11)
Cirrhosis, hepatitis B-related 37 (3.7)
Cirrhosis, metabolic 54 (5.3)
Cirrhosis, other 143 (14)
Cholestatic, PBC/PSC/other 196 (19)
Retransplant, acute liver failure 36 (3.6)
Retransplant, chronic liver failure 125 (12)
Other/unknown 58 (5.7)
Donor/recipient blood group compatibility
Identical 938 (93)
Compatible 74 (7.3)
Liver/kidney transplantation 31 (3.1)
High urgent status at transplantation 153 (15)
Medical history, n (%)
Diabetes mellitus 208 (21)
Angina pectoris 27 (2.7)
Cerebrovascular disease 16 (1.6)
Hypertension 186 (18)
Cardiac intervention 27 (2.7)
Previous LT (reTX) 161 (16)
Previous major abdominal surgery (including reTX) 286 (28)
Hepatocellular carcinoma 179 (18)
Other malignancy 27 (2.7)
Previous encephalopathy 250 (25)
Previous ascites 448 (44)
Serology, n (%)
HBsAg-positive 74 (7.3)
HBcAb-positive 183 (18)
HCVAb-positive 148 (15)
HIVAb-positive 2 (0.2)
Clinical factors at transplant, n (%)
Encephalopathy 138 (14)
Ascites 352 (35)
Admitted at ICU 132 (13)
AST 83 (51-167)
ALT 55 (31-134)
GGT 79 (43-172)
Bilirubin 59 (26-194)
INR 1.4 (1.2-1.8)
Creatinine 83 (64-117)
Sodium 138 (135-141)
MELD score 16.4 (11.5-24.2)
MELDNa score 18.3 (12.5-26.2)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; IQR, interquartile range; HBcAb,
hepatitis B core antibodies; HIVAb, human immunodeficiency virus antibody; INR, international normal-
ized ratio; reTX: retransplant.
© 2018 Wolters Kluwer Blok et al 3at 40 and was rounded to the nearest whole value (range,
6-40). For the MELD sodium (MELDNa) score the formula
from the original study by Kim et al10 was used. The BAR
score was calculated, according to the formula described by
Dutkowski et al3 The factor major abdominal surgery was
defined and analyzed as follows: all types of major abdomi-
nal surgery such as bowel surgery exploratory laparotomy,
previous LT, liver surgery, and so on (examples of nonmajor
previous abdominal surgery: appendectomy, laparoscopic
cholecystectomy, pylorotomy) and categorized as either no
major abdominal surgery, previous LT, or other major ab-
dominal surgery. The factor perfusion fluid was categorized
as University of Wisconsin (UW) cold storage solution/other/
unknown versus histidine-tryptophan-ketoglutarate (HTK)
solution. A separate analysis of UW versus HTK, after exclu-
sion of other and unknown, showed similar results (data not
shown). To not lose too many patients for the study, we in-
cluded the other/unknown patients in the UW group, as they
showed similar results (data not shown).
To determine a set of prognostic factors for further study,
multivariate analyses were performed using Cox regression
models with backward elimination and forward selection.
Before multivariate analyses, all recipient laboratory values
with a nonnormal distribution (alanine aminotransferase,
aspartate aminotransferase, GGT, creatinine, and bilirubin)
and the ET-DRI were converted to a logarithmic scale. All
analyses were first performed 3 times; with the separateMELD
components (creatinine, International Normalized Ratio and
bilirubin), the calculated MELD score and the calculated
MELDNa score. Both models (MELD and MELDNa) were
significant, but because MELDNa was the more significant
model, this was used in all analyses. The factors that were sig-
nificant in these first set of multivariate analyses were then
used in the next part of the analyses. Next, all multivariate
Cox-regression analyses were performed separately for pa-
tient survival and graft survival (non–death-censored and
death-censored), defined as follows:
- Patient survival (PS): “the period between the date of trans-
plantation and date of recipient death, (independent for
cause of death).”
- Graft survival, non–death-censored (GSNC): “the period be-
tween the date of transplantation and date of recipient death
or date of retransplantation.”
- Graft survival, death-censored (GSDC): “the period between
the date of transplantation and date of retransplantation or
the date of reregistration on the waiting list, only if followed
by recipient death. Datawere censored as of the date of recip-
ient death for all patients that were not reregistered on the
waitlist. Note that using this definition of death-censored
graft survival, patients that were reregistered on the waiting
list, but were not retransplanted nor died directly after the re-
registration, were not regarded as graft failure.”
Administrative censoring applied at 3-months, 1-year, and
5-year follow-up. Administrative censoring was calculated
after “x” months, specific emphasis for the factors that
were significant at 3 months and so on. All analyses were
anonymized for transplant center. Subsequently, multivariate
analyses were performed, using all prognostic factors that
were selected (significant at 0.05 level) in at least one of the
previous analyses.
TABLE 3.
Donor and transplant characteristics for deceased donor
liver transplants performed in adults from 2002 to 2011 in
the Netherlands
Donor factors
Age: median (IQR), ya 49 (38-57)
Sex, n (%)
Male 508 (50)
Female 504 (50)
BMI, median (IQR) 24.4 (22.5-26.3)
Cause of death, n (%)a
Traumatic 230 (23)
CVA 666 (66)
Anoxic 67 (6.6)
Other 49 (4.8)
GGT, median (IQR), U/La 28 (17-53)
HBcAb-positive 18 (1.6)
HCVAb-positive n/a
DCDa 182 (18)
Transplant factor
Transplant center
4 Transplantation DIRECT ■ 2018 www.transplantationdirect.comz Values were calculated for all significant factors from the
multivariate analysis. The z value is the quotient of the regres-
sion coefficient of a risk factor and its standard error, with a
significance level at 1.96 (standard error). Negative values
have a protective effect for graft failure or patient death.
Harrell's concordance index (c-index)11 was calculated to
indicate the predictive capacity of the combination of fac-
tors at that specific time point and outcome type. The maximal
c-index of the combination of all factors in the multivariate
analysis was also calculated to get an indication of the max-
imal value that could be reached in this database (Supple-
mental Digital Content). Of course, such a model would be
totally overfitted and this was only done to obtain an upper
bound for a c-index in a clinical prediction model, based on
currently registered variables. A concept model (CM) was
constructed with the significant factors at 3 months patient
survival as a proof of principle and was compared with the
BAR score, DRI, ET-DRI, sRRI, and DRM by calculating
c-indices for all models over time (from 3 months till 5 years
posttransplant outcome). For all analyses, aWaldP value less
than 0.05 was considered significant. Analyses and the calcu-
lation of the c-index were performed with R (version 3.3.2).1 353 (35)
2 240 (24)
3 419 (41)
Perfusion fluid
UW 672 (66)
Unknown/other 73 (7.2)
HTK 267 (26)
Allocation, n (%)a
Local 305 (30)
Regional 424 (42)
Extraregional 283 (28)
Rescue allocation, N (%)a 60 (6)
Split LTa 23 (2.3)
2nd WIT, median (IQR), min 36 (28-44)
CIT, median (IQR), ha 7.7 (6.4-9.3)
ET-DRI, median (IQR) 1.67 (1.45-1.93)
aFactor in ET-DRI.
CVA, cerebrovascular accident; DCD, donation after circulatory determination of death; WIT, warm is-
chemia time.RESULTS
Donor, Transplant, and Recipient Factors
Included were 1012 deceased donor LTs, including 161 re-
peated transplants (16%), performed in the Netherlands in
adult recipients, with a mean follow-up of 7.9 years. Recipient
characteristics are shown in Table 2.Median recipient age was
52 years, with the majority of patients being transplanted for
cholestatic disease (19%) or alcoholic cirrhosis (15%) or vi-
ral cirrhosis due to hepatitis B virus or hepatitis C virus
(HCV) (14.8%).
Donor and transplant factors are shown in Table 3.Median
donor age was 49 years, the majority of donors had a cere-
brovascular accident as cause of death (66%), and 18% of
all allografts were obtained from donation after circulatory
death donors. Overall median ET-DRI donor risk was 1.67.
Multivariate Analysis of Recipient Risk Factors
A multivariate Cox regression analysis for 3 types of out-
come (patient survival, non–death- and death-censored graft
survival) at 3 time points (3-month, 1-year, and 5-year sur-
vivals) was performed. All the available recipient factors
(Table 2), perfusion fluid (UW/other or HTK), transplant
center, second warm ischemia time, and the ET-DRI were
included. This resulted in 9 separate analyses. The hazard
ratios of the factors that were significant at 1 or more points
in time are shown in Table 4 (PS) and Table 5 (GSNS and
GSDS). The c-index for the optimal combination of the sig-
nificant factors at that specific time point, for that specific
outcome type was calculated and shown below the involved
significant factors. The log-hazard ratios of the significant
factors are shown in Figure S1, SDC (http://links.lww.com/
TXD/A127).
Figure 1 shows the z values of the significant factors over
time for patient survival (Figure 1A), non–death-censored
graft survival (Figure 1B) and death-censored graft survival
(Figure 1C). The z value is the reflection of the importance
of that factor at that time point. These figures demonstrate
that the risk of every factor varies over time (short term vslong term) and changes when looking at either patient or
graft survival. For example, in Figure 1A, the importance of
the factor HCV antibody (HCVAb) for decreased patient
survival is negligible until about 6 months and becomes
and remains significant as of that point.
As a demonstration of this concept, the validity of the sig-
nificant recipient risk factors at 3-month patient survival,
recipient age (P < 0.001), MELD-Na (P < 0.001), and venti-
latory support (P < 0.001) were used to compose a “concept
model.” This CM is the most suited to predict patient sur-
vival at 3 months in this database (P < 0.001; c-index,
0.69) and is used in the following analyses as a surrogate re-
cipient risk model and subsequently for the sole reason to
function as a proof of principle.
Comparison of Risk Models
As a first step, the BAR score and ET-DRI were validated
in our data set for the type of outcome and time point they
were originally constructed for. The BAR score was validated
for 3-month patient survival (P < 0.001; c-index, 0.69). The
TABLE 4.
Results of the multivariate analysis of recipient risk factors according to 3-month, 1-year, and 5-year patient survivals
Patient survival
Exp. coefficient (95% confidence interval) 3 mo 1 y 5 y
Recipient age 1.03 (1.01-1.05) 1.02 (1.001-1.03) 1.02 (1.004-1.03)
Ventilatory support 3.00 (1.63-5.54) 2.33 (1.38-3.94) 2.26 (1.37-3.73)
MELDNa 1.05 (1.02-1.08) 1.05 (1.03-1.07) 1.03 (1.01-1.05)
HCVAb-positive 1.94 (1.28-2.94) 1.99 (1.41-2.84)
HCC 1.49 (1.05-2.10)
Malignancy 1.87 (1.02-3.44)
Diabetes mellitus 1.50 (1.12-2.02)
HBcAb-positive 0.64 (0.44-0.93)
Donor/transplant factor
Perfusion fluid (HTK vs UW/other) 1.37 (1.04-1.81)
C-index 0.69 (±0.031) 0.68 (±0.03) 0.68 (±0.02)
Exp, exponentiated; HCC, hepatocellular carcinoma.
© 2018 Wolters Kluwer Blok et al 5ET-DRI was validated for 5-year graft survival (P = 0.002;
c-index, 0.55).
Next, the c-indices of the DRI, ET-DRI, BAR-score, sRRI,
DRM, CM, and combination of CM with ET-DRI were
calculated (all as continuous models) for the 3 outcome
measures and 3 time points, to compare their predictive
capacity. The c-indices of these models are depicted in
Figure 2; for patient survival (Figure 2A), non–death-censored
graft survival (Figure 2B) and death-censored graft survival
(Figure 2C), the values are described in Table 6.
The change in the predictive capacity of the models is dem-
onstrated over time with the difference in c-indices per out-
come type (patient vs graft survival). The BAR score and
CM seem to have the highest c-index for short-term patient
survival (Figure 2A), but this decreases over time. As of circa
16 months of follow-up, the CM has the highest predictive
capacity for patient survival. For non–death-censored graft
survival (Figure 2B), the BARandCMhave comparable predic-
tive capacity at short-term survival, but the CM, CM/ET-DRI,
and DRM have the highest predictive capacity at the long-term
follow-up. For death-censored graft survival (Figure 2C), theTABLE 5.
Results of the multivariate analysis of recipient risk factors accor
death-censored graft survivals
Non–death-censored graft surviva
Exp. coefficient (95% confidence inte
Recipient factor 3 mo 1 y
Recipient age, y
Ventilatory support 2.01 (1.16-3.47) 1.65 (1.01-2.70)
MELDNa 1.02 (1.01-1.04) 1.0
HCVAb-positive 1.44 (1.01-2.05) 1.4
BMI
Donor/transplant factor
Perfusion fluid (HTK vs UW/other) 1.3
Combined liver-kidney transplant 0.14 (0.02-0.99) 0.3
logET-DRI 1.8
C-index 0.59 (±0.02) 0.59 (±0.02) 0
Exp, exponentiated.ET-DRI has a continuous higher predictive capacity than the
other risk models.
To show the absolute maximum of what may be possible
to achieve, the maximal c-indices of the combination of all
significant factors (Figure S2, SDC, http://links.lww.com/
TXD/A128) and the combination of all available factors
(Figure S3, SDC, http://links.lww.com/TXD/A129) were cal-
culated for all 3 outcome measurements. Of course, such
models are totally overfitted and therefore not usable in (clin-
ical) practice.DISCUSSION
This study provides insight into the changing importance
of (recipient) risk factors and donor/recipient risk models
over time (short term vs long term) and per outcome type (pa-
tient survival vs graft survival). The main focus of this study
was to demonstrate the differences in outcome type and pe-
riod (for the in this study included recipient risk factors). This
was demonstrated by analyzing a decade of LTs performed
in the Netherlands with a long-term follow-up (mean,ding to 3-month, 1-year, and 5-year non–death-censored and
l Death-censored graft survival
rval) Exp. coefficient (95% confidence interval)
5 y 3 mo 1 y 5 y
0.98 (0.96-0.99) 0.98 (0.97-0.998)
1 (1.00-1.03)
9 (1.11-1.99)
0.95 (0.90-0.99)
0 (1.02-1.67) 1.57 (1.06-2.32)
0 (0.10-0.93)
4 (1.08-3.13) 4.66 (1.60-13.6) 5.13 (2.03-13.0) 3.26 (1.36-7.81)
.59 (±0.02) 0.62 (±0.04) 0.62 (±0.03) 0.65 (±0.03)
FIGURE 1. A, Z values for recipient risk factors, perfusion fluid and
(log-)ET-DRI with patient survival as outcome over 5 years time. B,
z values for recipient risk factors, perfusion fluid and (log-)ET-DRI with
(non–death-censored) graft survival as outcome over 5 years time. C,
Z values for recipient risk factors, perfusion fluid and (log-)ET-DRI with
(death-censored) graft survival as outcome over 5 years' time.
FIGURE 2. A, Concordance indices of risk models with patient sur-
vival as outcome over 5 years' time. B, Concordance indices of risk
models with non–death-censored graft survival as outcome over
5 years' time. C, Concordance indices of risk models with death-
censored graft survival as outcome over 5 years' time.
6 Transplantation DIRECT ■ 2018 www.transplantationdirect.com7.9 years). The provided knowledge can be used to assess the
risks involved in clinical decision-making. Besides a great
variety in the factors that are used in the studied risk
models (either donor, transplant and/or recipient risk factors),
these models are incomparable when looking at the type of
outcome that is intended to predict: patient survival versus
graft survival and short-term versus long-term outcome. This
makes it difficult to perform a valid comparison with regard
to their capability of predicting outcome after LT, reflected
by the c-index.
The BAR score and ET-DRIwere first validated in the data
set for their original endpoint and outcome type. Addition-
ally, a multivariate analysis was performed including all
(available) recipient risk factors and significant donor and
transplant factors (ET-DRI and perfusion fluid) to determinewhich factors influence outcome after LT. As shown in
Figures 1A to C, the importance of the significant factors
varies over time and across outcome types. Factors with
an absolute z-value greater than 1.96 are significantly
TABLE 6.
C-indices of the investigated risk model for PS, GSNC, and
GSDC at 3 months, 1 year, and 5 years
Timepoint
3 mo 1 y 5 y
Risk model PS GSNC GSDC PS GSNC GSDC PS GSNC GSDC
BAR 0.69 0.70 0.55 0.65 0.65 0.54 0.60 0.57 0.54
ET-DRI 0.52 0.51 0.59 0.51 0.50 0.59 0.53 0.54 0.59
DRI 0.51 0.50 0.58 0.51 0.51 0.59 0.53 0.55 0.58
CM 0.69 0.69 0.58 0.65 0.64 0.56 0.62 0.60 0.57
CM + ET-DRI 0.64 0.64 0.50 0.61 0.61 0.52 0.61 0.60 0.50
DRM 0.63 0.63 0.49 0.62 0.62 0.52 0.61 0.60 0.52
sRRI 0.65 0.64 0.53 0.63 0.62 0.52 0.61 0.59 0.52
© 2018 Wolters Kluwer Blok et al 7associated with outcome (Tables 4 and 5). As a demonstra-
tion of this principle, the significant factors at 3-month
patient survival (recipient age, ventilatory support and
MELDNa) were used to construct a concept model. This
is to demonstrate that a risk model changes (or should
change) per chosen type of outcome (in this case patient
survival) and point in time (in this case short-term [3months]
follow-up). The factors included in the appropriatemodel are
chosen according to or determined by to results of the multi-
variate analysis for that specific time point and outcome type.
So, in this case, we created a risk model that is the most ap-
propriate to predict 3-month patient survival, consisting of
the 3 significant factors at that time point: recipient age,
MELD-Na and ventilatory support. The comparison of
c-indices showed that the combination of factors significant
at short-term (3months) patient survival are important to in-
dicate short-term patient risk, but also long-term patient and
graft survival (purple line in Figures 2A and B). In our data-
base, the CM was comparable to the BAR-score for short-
term outcome and seemed superior to all other models for
long-term outcome.
When looking at non–death-censored graft survival, the
CM and BAR had comparable c-indices short-term, but the
CM was comparable to the combination of ET-DRI with
the CM and the DRM (long term). The results of the death-
censored graft survival analyses showed that the ET-DRI
has the highest c-index over time and would have our prefer-
ence to the other risk models. Overall, our results clearly
show that patient survival mainly depends on the condition
of the recipient, whereas death-censored graft survival pre-
dominantly depends on the quality of the liver graft itself.
Non–death-censored graft survival reflects both, which is a
consequence of its definition. Even though the outcome of a
complex procedure like an LT is very difficult to predict, we
have shown the best predictive models (in our opinion) with
their limitations. Although limited, these models are still
much better than not validated, sometimes only theoretical
parameters or even expert opinion. Furthermore, predictive
models are essential in case-mix correction and/or outcome
analysis. The results of our analyses actually show that the risk
factors that were significantly associated with outcome are also
relevant after a longer period. These factors aremost relevant at
the time of transplantation when selecting a suitable recipient.
For evaluation of outcome or for deciding whether to ac-
cept an organ offer or not, it is essential to understand thedifferences of predictive tools with regard to time and out-
come. When comparing outcome data between various cen-
ters, regions, or countries, the data suggest that the DRM
(combination of ET-DRI and sRRI) has the highest potential.
Of all previously described models, the DRM gives a valid
prediction of long-term patient and non–death-censored
graft survival (c-index of 0.60). Furthermore, the DRM con-
sist of a combination of donor, transplant, and recipient fac-
tors that are all available in most databases (UNOS and
Eurotransplant). Donor quality is probably best reflected in
death-censored graft survival analyses. The DRI and ET-DRI
models best predict this outcome type, which is why we
therefore prefer these models to describe donor quality. For
short-term patient survival, one could either use the BAR
score or CM.We prefer the latter because this model only in-
cludes recipient factors. In fact, the CM has the same param-
eters as the BAR, with the addition of donor age, CIT,
retransplantation, and MELD-Na instead of MELD. Inter-
estingly, retransplantation was not identified as a risk factor
in this database.
This study has certain limitations. Because it is based on a
retrospective database (from a single country), all donor-
recipient combinations were already chosen by the trans-
plant center, and liver allografts were allocated centrally
(by Eurotransplant). The consequence is that certain (extreme)
risk factors could have been missed due to not accepting such
an organ for an LT. Theoretically, in a larger study cohort,
there could be a chance of findingmore significant risk factors;
nevertheless, we proved that the abovementioned factors are
of significant impact on outcome after LT in the Netherlands.
In the end, the doctor in charge should overview all clinical data
of the donor and the recipient before accepting the offer. It is
difficult to weigh all factors, which is why risk models can be
helpful in assessing the specific risks of the donor organ or re-
cipient at the time of transplantation. In the analyzedmodels,
every relevant risk factor seems to be included. A better pre-
diction model or model with a higher c-index would there-
fore only be possible if other factors were added to one of
these models. However, the question rises if it would even
be possible to achieve such a higher c-index, because this
would only be possible at the risk of overfitting the model
to a specific database and thus losing the generalizability
for a broader transplant population. Even though our recip-
ient population differs from that in (for example) the United
States, looking at the distribution of etiology of disease. In
our database, themajority of patients is suffering frombiliary
tract related/cholestatic disease or alcoholic disease, whereas
the majority of patients transplanted in the United States has
HCV-related cirrhosis or a malignancy.12 Nevertheless, we
corrected for the disease etiology in the multivariate analyses,
and we think our findings can also be applied in other re-
gions, such as the United States. Themain point is the varying
risk of etiology, such as, for example, hepatocellular carci-
noma or HCV (see above). Another issue was the missing
values of CIT and GGT. To calculate the risk models for ev-
ery transplantation, the median values of these factors were
used as imputation. Because of the limited missing number
of values, this will not have influenced or led to any bias in
the analyses. With regard to the analyses, it would have been
possible to use competing risk analyses for this study. How-
ever, competing risks only play a role in death-censored graft
survival, where death of the recipient precludes graft failure.
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graft survival are based on so-called cause-specific hazards
models. These models are valid also in the presence of com-
peting risks and are actually recommended when interest lies
in the etiology of the prognostic factors/indices involved.13,14
The Fine-Gray model is an alternative, but we felt that the
cause-specific hazards models that we present are more ap-
propriate and closer to the proportional hazards models that
were used for the other outcomes. The fact that we found
perfusion fluid as a risk factor could potentially have been
caused by selection bias. A possible explanation could be that
the difference in outcome for UW- and HTK-related trans-
plants is due to themore frequent use of HTK in earlier years,
which potentially have less results, whereas in more recent
years, UW has preferably been used as perfusion fluid of
choice in the Netherlands. A recent study with Eurotransplant
data showed that the differences in outcome are explained by
regional differences in donor, recipient, and transplant charac-
teristics. After adjustment for these factors, these differences in
outcome disappeared (de Boer et al Transplantation, 2018—
accepted manuscript). The same effect could be applicable
for a difference in transplant period (era). Nevertheless, perfu-
sion fluid was found as a significant factor in this study and
has therefore been corrected for.
The 3 factors of the CM (recipient age, ventilatory support,
and MELDNa) were significantly associated with short-term
patient survival. Of those 3 factors, MELDNa was also signif-
icantly associated with outcome at all time points and for both
patient and death-uncensored graft survival (Tables 4 and 5).
The impact of pretransplant sodium in the transplant candi-
date on outcome has been described previously10,15 and is a
known risk factor. We choose here to use MELDNa instead
of MELD because it had a higher predictive capacity in our
data set (data not shown). TheMELDNamodel is not (yet) be-
ing used for liver allocation in the Netherlands (nor the rest of
ET). In UNOS, however, theMELDNa has been incorporated
for liver allocation in patients with a MELD score above 11
since January 2016.16 Based on these data, wewould advocate
that Eurotransplant also incorporates sodium into the MELD
score. In the previously constructed sRRI, the MELD score
was used, because MELDNa was not available in the
Eurotransplant database, but when looking at the current
data, it would be interesting to alter this to MELDNa. Even
in a population where the median MELDNa at transplant is
substantially higher than in our database, our findings are still
useful. When a prognostic model is applied in a context where
the median MELDNa is substantially higher, the resulting
probabilistic predictions from that model will be different,
but it does not mean that the contributions of the factors in
that model change. That will be the case when the “effect”
of the covariates is different when Na-MELD is higher or
lower. In statistical terms, that is the case when there is an in-
teraction between Na-MELD and other factors. We have
checked for this, and we did not find any significant interac-
tions between Na-MELD and other factors for none of the 3
types of outcome considered here.
A recent publication on donor-recipient matching by
Briceño et al17 addressed the difficulties with these types of
(predictive) models and gave a complete overview of the cur-
rent situation with regard to existing risk models. The same
authors studied the use of artificial intelligence (artificial neu-
ral networks) in donor-recipient matching and prediction of3-month graft survival as alternative to the current existing
predictive models.18 They also addressed the limitations
of available predictive models, such as the DRI, MELD
(when used as predictor of posttransplant survival19), SOFT,
D-MELD, or BAR score, that all had lower areas under the
curve as compared with their artificial neural networks. In-
terestingly, they describe the high risk of overfitting, because
the high number (>55) of variables was solved by the self-
learning process of the artificial neural networks, but the
question remains if this system would be useable in the daily
practice because of its complexity. Also, such a model would
almost certainly be severely overfitted, meaning that it would
fit very well on these data, but not so well on other, compara-
ble data. Furthermore, because it is suited for 1 center or re-
gion specifically, it cannot be used to compare outcome
data between different centers, regions, or countries.
It seems that, when looking at the predictive capacity of
the investigated risk models, graft survival is more difficult
to predict than patient survival; the c-indices are generally
lower in the graft survival figures (Supplemental Digital Con-
tent). The fact that the various models function differently
with different outcome types and times is a logical conse-
quence of their design to predict this specific outcome type
or time. For example, donor risk has less impact on the predic-
tion of patient survival (lower c-indices for DRI/ET-DRI), but
this increases when looking at graft survival and when fol-
low-up time increases. This suggests that 1 model would be
preferable over another model for short-term survival, but
another model would be more suitable when one is looking
for prediction of long-term survival. Ideally, one would be
able to create an LT “risk equalizer” that adjusts the risk of
a certain factor according to the moment in time and the cho-
sen outcome type. We think that this study is a first step to-
ward, such a risk equalizer and the methods described here
would make it possible to create such a tool. However, the
data in the database used for this study are too limited in
numbers to create such a model, and our aim was not to cre-
ate a new risk model, but to demonstrate the steps to do so.
Furthermore, before introducing another (new) model, this
should first be tested and validated in another database, pref-
erably from other countries/regions, to ensure its strength.
Follow-up studies to verify these findings would be interest-
ing to undertake. In the meantime, our suggestion would be
to look at patient survival for short-term prediction purposes
and non–death-censored graft survival for long-term predic-
tion purposes. Even though our results showed that long-
term outcome is more difficult to predict, a reasonable risk
indication can be achieved with the currently available risk
models (eg, ET-DRI and sRRI). This pretransplantation
risk indication can be used to improve donor-to-recipient
matching (or selection) and optimize utilization in an era of
organ scarcity.CONCLUSIONS
In our opinion, this study contributes to the concept of risk
factors and models. Although these models have their limita-
tions, they are currently the best predictors of outcome. It is
important to define and clearly describe which type of out-
come and point in time one aims to predict (dynamic end-
points). A decade of LT in the Netherlands was analyzed
and used to demonstrate the effects of recipient risk factors
© 2018 Wolters Kluwer Blok et al 9and risk models on different outcome types and posttrans-
plantation time points. Short-termpatient survival mainly de-
pends on recipient risk factors, whereas long-term graft
survival (death-censored) mostly depends on donor risk
factors. For these purposes, respectively, the BAR model
and ET-DRI showed a satisfactory discriminative capacity.
Long-term outcome is more difficult to predict, but next to
the CM, the DRM has a higher predictive capacity to other
riskmodels for (long-term) patient and especially non–death-
censored graft survival. The DRI and ET-DRI were the best
predictors of death-censored graft survival and therefore best
describe the quality of the donor liver itself. Knowledge
about risk factors and models is critical when looking at out-
come or comparing results and is an essential asset in waiting
list management and organ allocation.
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